Does GLICLAZIDE Cause Poor venous access? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Poor venous access have been filed in association with GLICLAZIDE. This represents 0.1% of all adverse event reports for GLICLAZIDE.
6
Reports of Poor venous access with GLICLAZIDE
0.1%
of all GLICLAZIDE reports
0
Deaths
3
Hospitalizations
How Dangerous Is Poor venous access From GLICLAZIDE?
Of the 6 reports, 3 (50.0%) required hospitalization.
Is Poor venous access Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for GLICLAZIDE. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does GLICLAZIDE Cause?
Hypoglycaemia (756)
Nausea (596)
Acute kidney injury (553)
Drug ineffective (507)
Fall (415)
Dyspnoea (400)
Vomiting (385)
Lactic acidosis (373)
Malaise (360)
Hypertension (351)
What Other Drugs Cause Poor venous access?
VEDOLIZUMAB (1,043)
INFLIXIMAB (917)
INFLIXIMAB-DYYB (782)
ECULIZUMAB (555)
HUMAN IMMUNOGLOBULIN G (504)
NATALIZUMAB (422)
RITUXIMAB (299)
TOCILIZUMAB (287)
METHOTREXATE (257)
ABATACEPT (249)
Which GLICLAZIDE Alternatives Have Lower Poor venous access Risk?
GLICLAZIDE vs GLIMEPIRIDE
GLICLAZIDE vs GLIMEPIRIDE\ROSIGLITAZONE
GLICLAZIDE vs GLIPIZIDE
GLICLAZIDE vs GLIVEC
GLICLAZIDE vs GLOFITAMAB